BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tysabri (natalizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tysabri (natalizumab)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05418010-17@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tysabri (natalizumab): Phase 2 readout est. (NCT05418010)
DESCRIPTION:Tysabri (natalizumab)\, phase 2\, Multiple Sclerosis.\nStudy: N
 atalizumab for the Treatment of People With Inflammatory Demyelination Sug
 gestive of Multiple Sclerosis\, or Definite Multiple Sclerosis\, at First 
 Presentation (AttackMS)\nEstimated primary completion: 31 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/natalizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05418010
URL:https://assetmemo.bio/drug/natalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07892027-17@assetmemo.bio
DTSTAMP:20261121T005714Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Tysabri (natalizumab): Phase 2 readout est. (NCT07892027)
DESCRIPTION:Tysabri (natalizumab)\, phase 2.\nStudy: Natalizumab for the Pr
 evention of ICANS in Patients With Recurrent or Refractory Diffuse Large B
 -Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy\nEstim
 ated primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/natalizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07892027
URL:https://assetmemo.bio/drug/natalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
